Crestor and Apixaban Interaction: What Prescribers and Patients Should Know

Why This Combination Comes Up So Often

Patients who need apixaban typically carry diagnoses like atrial fibrillation (AF) or venous thromboembolism (VTE), conditions that frequently coexist with cardiovascular risk factors requiring statin therapy. The overlap is large. In the ARISTOTLE trial (N=18,201), over 30% of randomized participants were already receiving a statin at baseline [1]. Prescribers see this pair on medication reconciliation lists daily.

The Clinical Scenario

A 67-year-old with nonvalvular AF and an LDL of 142 mg/dL gets started on apixaban 5 mg twice daily and rosuvastatin 20 mg once daily at the same visit. The question of whether these two drugs interact is practical, not theoretical. It affects whether the prescriber needs to alter timing, doses, or monitoring.

Why Rosuvastatin Specifically

Among statins, rosuvastatin is one of the least likely to interact with CYP3A4-dependent drugs. Unlike atorvastatin, lovastatin, and simvastatin (all significantly metabolized by CYP3A4), rosuvastatin is primarily metabolized by CYP2C9 with minor CYP2C19 involvement [2]. This metabolic separation is the pharmacokinetic foundation for the drug pair's favorable safety profile.

Mechanism of Interaction: CYP Enzymes, P-gp, and BCRP

The interaction profile between rosuvastatin and apixaban involves three systems: cytochrome P450 enzymes, P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP). Understanding each layer clarifies why this combination is lower-risk than many statin-anticoagulant pairs.

CYP3A4: The Pathway That Matters Most for Apixaban

Apixaban undergoes hepatic metabolism primarily through CYP3A4, with minor contributions from CYP1A2 and CYP2J2. According to the FDA-approved Eliquis label, strong dual inhibitors of CYP3A4 and P-gp (such as ketoconazole or ritonavir) reduce apixaban clearance by approximately 50%, prompting a dose reduction to 2.5 mg twice daily [3]. Rosuvastatin does not inhibit or induce CYP3A4. The rosuvastatin prescribing information confirms that the drug is not a meaningful substrate, inhibitor, or inducer of CYP3A4 [4]. This means rosuvastatin will not increase or decrease circulating apixaban concentrations through this pathway.

P-glycoprotein Transport

Apixaban is a substrate of the P-gp efflux transporter. Strong P-gp inhibitors can raise apixaban plasma levels by reducing intestinal and biliary efflux. Rosuvastatin is not a P-gp inhibitor. A 2018 pharmacokinetic review in the British Journal of Clinical Pharmacology confirmed that rosuvastatin has no clinically relevant P-gp inhibitory activity at therapeutic doses [5]. This removes the second major mechanism through which a co-administered drug could raise apixaban exposure.

BCRP: The Shared Transporter

Both rosuvastatin and apixaban are substrates of BCRP, an efflux transporter expressed in the intestine, liver, and kidneys. Theoretically, competition at BCRP could increase the absorption of one or both drugs. In practice, the clinical significance is small. A pharmacogenomic study of the ABCG2 c.421C>A polymorphism (which reduces BCRP function) found that rosuvastatin AUC increased by approximately 144% in homozygous carriers compared to wild-type individuals [6]. Apixaban's reliance on BCRP for elimination is more modest. The net effect of two substrates competing at one transporter, without either acting as a potent inhibitor, has not produced clinically significant pharmacokinetic changes in published data.

Severity Rating Across DDI Databases

Major drug interaction databases classify the rosuvastatin-apixaban pair consistently. The combination does not appear in the FDA's contraindicated or "avoid" categories for either drug.

Database Consensus

Lexicomp rates the interaction as "no known interaction" or "monitor therapy" depending on version and clinical context. Micromedex does not flag the combination as moderate or major. Clinical Pharmacology (Elsevier) similarly omits it from higher-risk tiers. This stands in contrast to the simvastatin-apixaban pairing, where shared CYP3A4 metabolism raises the possibility of bidirectional concentration changes [7].

What "Monitor Therapy" Actually Means

When a database assigns "monitor therapy," it signals that co-administration is acceptable but that standard clinical vigilance should continue. For this pair, that means tracking renal function (because apixaban dose depends on creatinine clearance, body weight, and age), watching for unexpected bleeding or bruising, and confirming that LDL-C goals are being met on the chosen rosuvastatin dose. No special lab timing or dose staggering is required.

Comparison to Other Statin-Apixaban Pairs

Not all statins carry the same interaction profile with apixaban. The metabolic route matters.

CYP3A4-Dependent Statins

Simvastatin and lovastatin are prodrugs extensively metabolized by CYP3A4. Co-administration with CYP3A4 inhibitors has produced 10- to 20-fold increases in statin exposure in pharmacokinetic studies, which is why the simvastatin FDA label contraindicates use with strong CYP3A4 inhibitors [8]. While apixaban is a CYP3A4 substrate (not an inhibitor), using a CYP3A4-dependent statin introduces a shared metabolic bottleneck. If a third drug inhibiting CYP3A4 enters the regimen, both the statin and apixaban could see elevated levels simultaneously.

Atorvastatin is partially CYP3A4-dependent but less vulnerable than simvastatin. A population pharmacokinetic analysis from the ENGAGE AF-TIMI 48 dataset found no significant effect of atorvastatin co-administration on edoxaban (another DOAC) pharmacokinetics, suggesting the practical risk with moderate CYP3A4-metabolized statins may be low [9]. Rosuvastatin avoids this layer of complexity entirely.

Pravastatin and Pitavastatin

Like rosuvastatin, pravastatin and pitavastatin bypass CYP3A4. Pravastatin undergoes non-CYP enzymatic metabolism and sulfation. Pitavastatin is minimally metabolized by CYP2C9 with limited CYP3A4 involvement. Either could serve as an alternative to rosuvastatin in patients taking apixaban, though rosuvastatin's potency advantage (greater LDL-C reduction per milligram) often makes it the preferred choice. In the JUPITER trial (N=17,802), rosuvastatin 20 mg reduced LDL-C by 50% and cut first cardiovascular events by 44% compared to placebo [10].

Monitoring Recommendations

No special monitoring protocol is needed solely because rosuvastatin and apixaban are used together. Standard monitoring for each drug independently covers the relevant parameters.

For Apixaban

The 2023 American Heart Association scientific statement on DOAC management recommends annual renal function assessment (or more frequently in patients with CrCl 30 to 50 mL/min), periodic complete blood count, and clinical vigilance for bleeding signs [11]. The apixaban dose reduction criteria remain unchanged by rosuvastatin co-administration: reduce to 2.5 mg twice daily if the patient meets at least two of three criteria (age ≥80 years, body weight ≤60 kg, serum creatinine ≥1.5 mg/dL).

For Rosuvastatin

Baseline and follow-up lipid panels (fasting or non-fasting) at 4 to 12 weeks after initiation or dose change, then every 3 to 12 months per the 2018 AHA/ACC cholesterol guideline [12]. Hepatic transaminase measurement is no longer mandated routinely by the FDA for statins, but clinicians may check ALT at baseline. Report unexplained muscle pain, as rhabdomyolysis risk exists with all statins regardless of anticoagulant status.

When to Reassess the Pair

Reassessment is appropriate when a third drug enters the regimen that strongly inhibits or induces CYP3A4 or P-gp. Examples include clarithromycin, itraconazole, rifampin, carbamazepine, and certain HIV protease inhibitors. These agents can shift apixaban exposure enough to require dose changes or drug substitution. Rosuvastatin itself will not be the source of such a shift, but the overall regimen complexity increases with each new medication.

Patient Counseling Points

Prescribers and pharmacists should address three areas when patients ask about taking Crestor and Eliquis together.

Timing and Administration

Both drugs can be taken without regard to food. There is no requirement to separate doses by a specific interval. Patients taking rosuvastatin at bedtime and apixaban twice daily (morning and evening) can continue that schedule without modification.

Signs to Report

"Patients on any anticoagulant should know the warning signs of bleeding: prolonged nosebleeds, blood in urine or stool, unusual bruising, and persistent headache," states the AHA's 2023 DOAC guidance [11]. These apply to apixaban regardless of statin choice. For rosuvastatin specifically, patients should report unexplained muscle tenderness or dark-colored urine.

Over-the-Counter Considerations

"Concomitant use of aspirin and anticoagulants increases bleeding risk and should be carefully evaluated," notes the 2019 AHA/ACC/HRS atrial fibrillation focused update [13]. NSAIDs such as ibuprofen and naproxen raise the same concern. Patients should check with their pharmacist before adding any OTC pain reliever or supplement (particularly fish oil at high doses or vitamin E) while on apixaban.

Special Populations

Renal Impairment

Apixaban is approximately 27% renally eliminated. In patients with severe renal impairment (CrCl 15 to 29 mL/min), apixaban exposure increases modestly [3]. Rosuvastatin exposure also rises in severe renal impairment. The rosuvastatin label recommends a starting dose of 5 mg daily in patients with CrCl <30 mL/min and a maximum dose of 10 mg daily [4]. These adjustments are independent of each other but both apply simultaneously in patients with advanced CKD.

Hepatic Impairment

Rosuvastatin is contraindicated in active liver disease or unexplained persistent transaminase elevations. Apixaban has not been studied in patients with severe hepatic impairment (Child-Pugh C) and is not recommended in that population. In mild to moderate hepatic impairment, both drugs can be used with appropriate monitoring.

Elderly Patients

Patients aged 75 and older represent the population most likely to receive both drugs simultaneously. Age alone does not change the interaction profile, but it does affect apixaban dosing criteria and increases susceptibility to statin-related myopathy. A 2020 meta-analysis in The Lancet covering 28 statin trials (N=186,854) confirmed that statin benefit persists in patients over 75, particularly for secondary prevention [14]. The benefit-risk calculation favors continued co-prescription in most elderly patients.

The Bottom Line on This Drug Pair

The rosuvastatin-apixaban combination is pharmacokinetically favorable because it avoids the CYP3A4 bottleneck that complicates other statin-anticoagulant pairs. BCRP substrate overlap exists but has not produced clinically meaningful pharmacokinetic changes in published studies. Neither drug's FDA label flags the other as a concerning co-medication. For patients who need both lipid-lowering and anticoagulation, rosuvastatin is among the safest statin choices to pair with apixaban. Annual renal function testing, periodic lipid panels, and standard bleeding surveillance remain the appropriate monitoring strategy.